Sort
48,018 grants matching “immunotherapy”
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions
$402,500E. Ashley Moseman · Duke University · R01 · FY2021 · NS
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · AG
Non-racemic metabolic biomaterials for HFpEF
$402,500Andrei Maiseyeu · Case Western Reserve University · R01 · FY2022 · HL
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · AG
Non-racemic metabolic biomaterials for HFpEF
$402,500Andrei Maiseyeu · Case Western Reserve University · R01 · FY2021 · HL
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions
$402,500E. Ashley Moseman · Duke University · R01 · FY2022 · NS
Innate Antiviral Signals for Cancer Immunotherapy
$402,500Matthias Gromeier · Duke University · R01 · FY2025 · NS
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$402,500Peiwen Chen · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · NS
Treatment of Primary Amoebic Meningoencephalitis via Modulation of Antibody Effector Functions
$402,500E. Ashley Moseman · Duke University · R01 · FY2023 · NS
Molecular Mechanisms in Gastrointestinal Stromal Tumor
$402,500Ronald P Dematteo · University Of Pennsylvania · R01 · FY2020 · CA
Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease
$402,500Dianne M Perez · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · AG
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity
$402,489Joseph Dougherty · Rbhs-Robert Wood Johnson Medical School · R33 · FY2016 · AI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
$402,467Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2024 · NS
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$402,460Robert M Prins · University Of California Los Angeles · R01 · FY2023 · CA
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$402,457Robert M Prins · University Of California Los Angeles · R01 · FY2022 · CA
Development of mAb therapeutics against biothreat and emerging diease agents
$402,448Thomas Briese · Columbia University Health Sciences · U54 · FY2012 · AI
Insonation of ultrasound microbubbles at low frequency to enhance image-guided therapy
$402,443Katherine W Ferrara · Stanford University · R01 · FY2018 · CA
COMBINING NANOTECHNOLOGY AND RADIATION TO ENHANCE CHECKPOINT BLOCKADE IMMUNOTHERAPY OF ADVANCED PROSTATE CANCER
$402,428University Of Chicago · · FY2018 · Defense Health Agency
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$402,417Fumito Ito · University Of Southern California · R01 · FY2022 · CA
Antitumor potential of AvFc lectibody in non-small cell lung cancer
$402,402Nobuyuki Matoba · University Of Louisville · R21 · FY2023 · CA
Development of a PET CCR2 Imaging Agent to Profile PDAC Microenvironment
$402,401Mark Myron Goodman · Emory University · R21 · FY2024 · CA
Dissecting the structure-function relationship of the Wnt destruction complex condensate
$402,400Maxwell Zane Wilson · University Of California Santa Barbara · R21 · FY2025 · CA
Targeting CXCR2+ PMN-MDSCs for immunotherapy of hepatoblastoma
$402,400Xin Chen · University Of Hawaii At Manoa · R21 · FY2025 · CA
Matrix assembly and remodeling during S. aureus biofilm development
$402,400Kenneth W. Bayles · University Of Nebraska Medical Center · P01 · FY2018 · AI
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
$402,394Benjamin Alan Youngblood · St. Jude Children'S Research Hospital · R01 · FY2022 · CA